Clinical trials: sponsored by Merck Sharp & Dohme LLC
Advanced Solid Tumor, Esophageal Cancer
A Study of PRT3789 in Combination With Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation
This is a Phase 2 an open-label, multi-center study to determine the safety, tolerability, efficacy, pharmacokinetics, pharmacodynamics, and anti-tumor activity of PRT3789 in combination with pembrolizumab in patients with…
- Conditions
- Advanced Solid Tumor, Esophageal Cancer, Metastatic Solid Tumor, Non-small Cell Lung Cancers
- Trial name
- NCT06682806
- Testing
- PRT3789, pembrolizumab
- Where
- 9 sites in United States, Spain
- Volunteers
- 6 people
- Sponsor
- Prelude Therapeutics Incorporated
HIV I Infection, Cardiovascular Risk Factor
Doravirine Versus Integrase Inhibitors on Backbone of Emtricitabine and Tenofovir Alafenamide in HIV
This research application will explore the impact of the Non-nucleoside reverse transcriptase inhibitor (NNRTI) doravirine in the setting of established Nucleoside reverse transcriptase inhibitors (NRTIs) backbone [Tenofovir…
- Conditions
- HIV I Infection, Cardiovascular Risk Factor, Lipid Metabolism Disorders
- Trial name
- NCT04820933
- Testing
- Doravirine 100 Mg
- Where
- 2 sites in United States
- Volunteers
- 26 people
- Sponsor
- University of Texas Southwestern Medical Center
Lymphoma
Study of Vorinostat (MK-0683) With Follicular Lymphoma (FL), Other Indolent B-cell Non-Hodgkin's Lymphoma (B-NHL), or Mantle Cell Lymphoma (MCL) Participants (MK-0683-103)
The purpose of this study is to evaluate the safety, tolerability, and efficacy of vorinostat (MK-0683) in participants with relapsed and/or refractory follicular lymphoma.
- Trial name
- NCT00875056
- Testing
- Vorinostat
- Volunteers
- 56 people
- Sponsor
- Merck Sharp & Dohme LLC
Healthy
A Study of Rifabutin and MK-4646 in Healthy Participants (MK-4646-004)
Researchers have designed a new study medicine called MK-4646 as a new way to treat human immunodeficiency virus (HIV). Rifabutin is a medication used to treat tuberculosis (TB).
- Trial name
- NCT07199452
- Testing
- MK-4646, Rifabutin
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Breast Cancer
A Study Of Changes In PD-L1 Expression During Preoperative Treatment With Nab-Paclitaxel And Pembrolizumab In Hormone Receptor-Positive Breast Cancer
This research study is exploring chemotherapy in combination with immunotherapy (a therapy that uses the body's own immune system to control cancer) as a possible treatment for hormone receptor positive breast cancer.
- Trial name
- NCT02999477
- Testing
- Pembrolizumab, Nab-Paclitaxel, Biopsy
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Adrienne G. Waks
Healthy
A Clinical Study of MK-8527 in Healthy Adult Participants (MK-8527-014)
Researchers are looking for new medicines to prevent Human Immunodeficiency Virus Type 1 (HIV-1) infection. HIV-1 is the most common type of HIV, which is a virus that attacks cells of the immune system.
- Trial name
- NCT07063238
- Testing
- MK-8527, Moxifloxacin
- Where
- United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Advanced Solid Tumor Malignancy
CyPep-1 Injections in Cancer Inducing Lymphocyte Infiltrate Accumulations
This Phase I/IIa trial is designed to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of CyPep-1 when administered directly into malignant tumors in monotherapy and in combination with anti programmed cell…
- Trial name
- CICILIA (NCT04260529)
- Testing
- CyPep-1, Pembrolizumab 25 MG/ML [KEYTRUDA®]
- Where
- 8 sites in France, Netherlands and 1 more
- Volunteers
- 60 people
- Sponsor
- Cytovation AS
Metastatic Non-small-cell lunG Cancer
PembRolIzuMab and Stereotactic Body Radiotherapy In Metastatic Non-small-cell lunG Cancer Patients
This is a single centre non-randomised open label phase 1 trial of lung SBRT to part of a lung lesion in patients with advanced NSCLC in combination with pembrolizumab.
- Trial name
- PRIMING (NCT03436056)
- Testing
- Stereotactic Body Radiotherapy (SBRT) 30 Gy 3 fractions (#), Stereotactic Body Radiotherapy (SBRT) 54 Gy 3 fractions (#), Stereotactic Body Radiotherapy (SBRT) dosed at the maximum tolerated dose
- Where
- United Kingdom
- Volunteers
- 2 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Non Small Cell Lung Cancer, Metastatic Melanoma
UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade
This is a phase I/II study that will evaluate the safety and toxicity of this combinatorial approach. Eligible patients >18 years of age with histologically proven metastatic NSCLC, melanoma, RCC, or HNSCC who have failed PD-1 /…
- Conditions
- Non Small Cell Lung Cancer, Metastatic Melanoma, Metastatic Renal Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
- Trial name
- NCT03474497
- Testing
- IL-2, Pembrolizumab, Radiotherapy
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- Megan Daly, MD
Breast Cancer
Converting HR+ Breast Cancer Into an Individualized Vaccine
Newly diagnosed post-menopausal women with clinical stage II-III, HR+HER2- breast cancer are eligible to a randomized trial, concurrently open at five US academic institutions.
- Trial name
- CBCV (NCT03804944)
- Testing
- Focal Radiation therapy, Pembrolizumab (200mg IV for 30 minutes, CDX-301
- Where
- 8 sites in United States
- Volunteers
- 100 people
- Sponsor
- Weill Medical College of Cornell University
Squamous Cell Carcinoma of Head and Neck
Pembrolizumab Plus Olaparib in LA-HNSCC
The purpose of this research study is to evaluate the effectiveness of using a combination of pembrolizumab and olaparib when given before and after standard chemoradiation therapy in treating locally advanced head and neck…
- Trial name
- NCT05366166
- Testing
- Pembrolizumab, Olaparib, Cisplatin
- Where
- 4 sites in United States
- Volunteers
- 45 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Squamous Cell Carcinoma of the Head and Neck
Efficacy Study of Pembrolizumab in Relapsed, Locally Recurrent Squamous Cell Cancer of the Head and Neck
The purpose of this study is to determine whether pembrolizumab, when given after salvage surgery, is effective in increasing the time a person with squamous cell cancer of the head and neck remains disease-free following…
- Trial name
- NCT02769520
- Testing
- Pembrolizumab
- Where
- 3 sites in United States
- Volunteers
- 27 people
- Sponsor
- Assuntina G. Sacco, MD
Metabolic Syndrome, Coronary Microvascular Dysfunction
Vericiguat in Patients With Metabolic Syndrome and Coronary Vascular Dysfunction
Coronary vascular dysfunction is one of the "final common pathways" for the impact of multiple cardiovascular risk factors. The investigators will conduct a randomized, double-blind placebo-controlled study in individuals with…
- Trial name
- NCT05711719
- Testing
- Vericiguat
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Johns Hopkins University
Cervical Cancer by FIGO Stage 2018, Squamous Cell Carcinoma FIGO 2018 Stage IIIA, IIIB, IIIC1-IIIC2
Pembrolizumab and Lenvatinib in Patients With High Risk Locally Advanced Cervix Cancer
The goal of this clinical trial is to learn if the combination of Pembrolizumab and Lenvatinib works to treat locally advanced cervical cancer in adults that will undergo primary chemoradiation and brachytherapy.
- Conditions
- Cervical Cancer by FIGO Stage 2018, Squamous Cell Carcinoma FIGO 2018 Stage IIIA, IIIB, IIIC1-IIIC2, Adenocarcinoma or Adeno-squamous Carcinoma Stage IB3-IIIC2
- Trial name
- NCT07368985
- Testing
- pembrolizumab and lenvatinib
- Where
- Netherlands
- Volunteers
- 87 people
- Sponsor
- Prof. Dr. Remi A. Nout
HIV-1 Infection
Dose Ranging, Switch Study of Islatravir (MK-8591) and Ulonivirine (MK-8507) Once-Weekly in Virologically-Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) [MK-8591-013]
This is a randomized, controlled, double-blind, study to evaluate the safety and tolerability of islatravir (ISL) + ulonivirine based on review of the accumulated safety data, in adult participants with human immunodeficiency…
- Trial name
- NCT04564547
- Testing
- Islatravir, Ulonivirine, BIC/FTC/TAF
- Where
- 23 sites in United States, France and 1 more
- Volunteers
- 161 people
- Sponsor
- Merck Sharp & Dohme LLC
Non Small Cell Lung Cancer, Breast Cancer
A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast Cancer
The main purpose of this study is to evaluate the safety and efficacy of abemaciclib in combination with pembrolizumab in participants with advanced non-small cell lung cancer (NSCLC) or hormone receptor positive (HR+), human…
- Trial name
- NCT02779751
- Testing
- Abemaciclib, Pembrolizumab, Anastrozole
- Where
- 24 sites in United States, Belgium and 5 more
- Volunteers
- 100 people
- Sponsor
- Eli Lilly and Company
Acute Lymphoblastic Leukemia, Pediatric
Vaccine Immune Recovery After Leukemia
This observational study aims to assess recovery of the immune system and immunity to vaccine-preventable diseases in children, adolescents, and young adults who recently completed treatment for acute lymphoblastic leukemia…
- Trial name
- VIRAL (NCT05622682)
- Testing
- Observational only: Serology and flow cytometry for ALL cohort participants, Observational only: Infection rates
- Where
- 6 sites in United States
- Volunteers
- 89 people
- Sponsor
- Children's Hospital of Philadelphia
Triple Negative Breast Cancer, Anthracycline-refractory TNBC
Docetaxel Chemotherapy and Pembrolizumab Plus Interleukin-12 Gene Therapy in Triple Negative Breast Cancer
The purpose of this research study is to test the safety and effectiveness of docetaxel chemotherapy and pembrolizumab plus adenoviral-mediated interleukin-12 (ADV/IL-12) gene therapy in patients with anthracycline-refractory…
- Trial name
- INTEGRAL (NCT04095689)
- Testing
- Docetaxel, Pembrolizumab, IL-12 gene therapy
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- The Methodist Hospital Research Institute
Acute Otitis Media (AOM)
V114 and Acute Otitis Media (V114-032/PNEU-ERA)
The primary objective is to evaluate V114 in the prevention of vaccine-type acute otitis media (VT-AOM) and the safety of V114 with respect to the proportion of participants with serious adverse events (SAEs) through completion…
- Trial name
- NCT04193215
- Testing
- V114, Pediatric vaccines
- Where
- 13 sites in Thailand
- Volunteers
- 7,119 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Ebola Virus Disease
Immunology of Ebola Vaccine
In this study 30 healthy adult participants will receive a single dose of an Ebola vaccine. Blood samples, fine needle aspirates, core biopsies, and bone marrow aspirates will be collected prior to and following vaccination to…
- Trial name
- NCT06100913
- Testing
- Recombinant Vesicular Stomatitis Vaccine for Ebola (rVSV∆G-ZEBOV-GP), Deuterium Labeled Water
- Where
- 2 sites in United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Emory University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.